The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Takumi, T., Tamada, K., Hatanaka, F., Nakai, N
Track changes in focus, memory, mood, and energy
c) In a clinical trial involving patients with IBD, BPC-157 supplementation resulted in improvements in immune markers and disease symptoms, indicating its immune-strengthening potential
Bioactive Materials, 32, 502-513
Am I a Good Candidate